Using Wearable Devices for Continuous Data Collection in Decentralized Clinical Trials

Wearable devices have become a cornerstone of modern GMP compliance in decentralized clinical trials (DCTs). These smart technologies allow for passive, continuous data collection from participants without requiring frequent clinic visits. From heart rate to blood oxygen levels and sleep patterns, wearables offer a scalable way to monitor trial participants in real time while supporting regulatory compliance and enhancing patient engagement. In this tutorial, we explore the types of wearable devices used in clinical trials, how they support data integrity, and best practices for implementation in DCTs.

What Are Wearable Devices in Clinical Trials?

Wearable devices are sensor-based, body-worn tools that track physiological metrics in real time or at set intervals. These devices often connect via Bluetooth or Wi-Fi and transmit data to centralized Electronic Data Capture (EDC) or cloud systems, enabling remote patient monitoring (RPM).

Key Metrics Captured by Wearables:

• Heart rate and heart rate variability (HRV)
• Electrocardiogram (ECG)
• Oxygen saturation (SpO₂)
• Respiratory rate
• Activity level and steps
• Sleep duration and quality
• Body temperature
• Blood glucose (in specialized continuous glucose monitors)

Popular Wearable Devices in Clinical Research:

• Fitbit: Used for tracking activity, sleep, and heart rate
• Apple Watch: Equipped with ECG and oxygen sensors
• Oura Ring: Detects sleep, temperature, and recovery
• BioIntelliSense BioSticker: Offers continuous multi-vital monitoring
• GlucoTrack and Dexcom: Monitor blood glucose non-invasively

Benefits of Wearable Data in DCTs:

1. Continuous Monitoring: Allows 24/7 data capture, identifying trends and anomalies
2. Improved Patient Experience: Reduces need for site visits and increases convenience
3. Real-Time Alerts: Enables immediate response to safety concerns
4. Objective Measurements: Enhances data reliability over self-reported outcomes
5. Protocol Compliance: Automatically logs and timestamps activities

Integration with Remote Monitoring Plans:

Wearables must be integrated into the trial’s Remote Patient Monitoring (RPM) plan, specifying:

• Type of device used and target metrics
• Data collection intervals
• Method of data transmission (e.g., app, cloud, EDC)
• Alert thresholds and escalation plans

This integration aligns with real-time stability studies and modern decentralized data models.

Data Flow and Validation Process:

To maintain data integrity and regulatory compliance, follow these steps:

• Ensure device is pre-validated and documented in the validation master plan
• Perform IQ/OQ/PQ on associated data platforms
• Capture data in a 21 CFR Part 11-compliant eSource platform
• Use audit trails and automated backup systems

Ensuring Participant Compliance and Training:

Wearables are only effective if participants use them consistently. Include the following in your plan:

• Clear instructions with visuals and videos
• Multilingual help resources and technical support
• Use of gamification or reminders to improve adherence
• Regular compliance tracking via apps or SMS

Regulatory Considerations:

Regulatory agencies like the EMA and TGA encourage innovation in DCTs but require robust evidence of device accuracy, calibration, and reliability. Include:

• Device manuals and validation data in submission dossiers
• Information on data handling, encryption, and cloud security
• Monitoring SOPs that reference device usage

Challenges and How to Overcome Them:

Best Practices for Trial Success:

• Select devices based on protocol endpoints and population demographics
• Pilot test wearables in a pre-trial phase
• Establish SOPs and contingency plans for device-related deviations
• Incorporate wearable data into centralized monitoring dashboards
• Align device data timelines with other clinical data sources

Case Study: Respiratory Clinical Trial Using BioSticker

A US-based respiratory study used BioIntelliSense BioSticker to continuously monitor respiratory rate, temperature, and activity. The data was integrated with an eSource platform and cross-validated with site assessments. The wearable detected early signs of exacerbations, allowing intervention before hospitalization. The use of AI and data analytics flagged high-risk participants, leading to improved outcomes and positive feedback from pharma regulatory requirements.

Conclusion:

Wearable devices have revolutionized continuous data collection in decentralized clinical trials. When properly selected, validated, and integrated into monitoring plans, wearables offer a seamless way to enhance patient safety, improve protocol compliance, and streamline data acquisition. As DCTs evolve, wearable technologies will remain critical in driving innovation, improving participant engagement, and meeting the expectations of global regulatory agencies.